Restoration Recovery is an outpatient addiction clinic with a location in Ringgold, Georgia, plus three clinics in Southeast Tennessee. We see patients weekly who are trying to make sense of what Georgia lawmakers are doing about kratom and 7-OH. This article is factual reporting on the legal landscape as of April 2026. It is not legal advice; if you have a specific legal question, consult a Georgia attorney. What we can speak to clinically is what treatment for kratom or 7-OH dependence looks like, and how it is unaffected by the regulatory questions playing out in Atlanta.

Where Georgia stands today

Kratom is legal for adults aged 21 and older in Georgia under the state’s 2019 Kratom Consumer Protection Act, as amended by HB181 effective January 1, 2025. The legal framework is regulatory rather than prohibitive: kratom and 7-OH products are sold through regulated retail channels, subject to age verification, labeling, laboratory testing, and display requirements. Violations carry civil penalties and product-seizure authority rather than criminal exposure for consumers.

That baseline is not necessarily stable. HB968, introduced in the 2026 legislative session, would reclassify mitragynine and 7-hydroxymitragynine as Schedule I controlled substances under Georgia law and repeal portions of the existing regulatory framework. If HB968 becomes law, Georgia would move from its current regulated-market status to a full prohibition similar to what is in place in Alabama and five other U.S. states. Whether that happens remains uncertain as of April 2026.

HB181 — the current regulatory regime

Georgia Governor Brian Kemp signed HB181 into law on May 2, 2024, with provisions taking effect January 1, 2025. The law amended the 2019 Kratom Consumer Protection Act by adding the following requirements.

Age verification

The minimum purchase age for any kratom or kratom-derived product in Georgia was raised from 18 to 21. Retailers must verify age before sale. Selling or transferring possession to anyone under 21 is a civil violation with fines starting at $1,000 and escalating for repeat offenses.

Display and access requirements

Kratom products must be kept either behind a display counter in an area accessible only to employees or in a secured display that requires employee assistance to access. Open-shelf display of kratom products by any Georgia retailer is no longer permitted.

Labeling standards

HB181 established specific labeling requirements. Every product sold at retail must disclose the mitragynine content and the 7-hydroxymitragynine content as separate line items, along with recommended serving size, safe consumption timeframe, batch or lot identifier, expiration date, and a visible warning prohibiting use by persons under 21. Labeling violations carry fines of up to $2,500 per violation, plus product-seizure authority for state officials.

Alkaloid concentration limits

The law caps 7-hydroxymitragynine at 2 percent of total alkaloid content in any kratom product sold in Georgia. This is a meaningful constraint because the concentrated 7-OH products drawing federal FDA attention, which the FDA describes as tablets, gummies, drink mixes, and shots with elevated 7-OH concentrations, would exceed this limit. HB181 also prohibits synthetic alkaloid additives and adulteration with non-kratom substances.

Testing and certification

Products sold in Georgia must be tested by a third-party laboratory for mitragynine content, 7-OH content, heavy metals, pesticides, bacteria, and mold. Certificates of Analysis (COA) must be made available to consumers on request or through scannable product codes.

HB757 — additional processor registration

HB757 layered additional requirements onto the HB181 framework at the processor level. Under HB757, any entity manufacturing or processing kratom products for sale in Georgia must annually register each kratom product with the Georgia Department of Agriculture, submit a certificate of analysis from a qualified third-party laboratory, and provide sworn certification that products are manufactured in FDA-registered facilities and are not adulterated with dangerous substances. The registration regime is designed to give state regulators a clear roster of products and manufacturers active in the Georgia market, with enforcement authority against any entity operating outside the registration framework.

For retail-facing enforcement, HB757 increases the state’s audit and compliance-review capacity over the products reaching Georgia shelves. The practical effect for Georgia consumers is a narrower menu of legally available kratom products compared to states without registration requirements.

HB968 — the Schedule I criminalization proposal

HB968, introduced in the 2026 Georgia General Assembly session, takes a fundamentally different regulatory philosophy. Rather than refine the consumer-protection framework HB181 and HB757 established, HB968 proposes to classify mitragynine and 7-hydroxymitragynine as Schedule I controlled substances under Georgia’s drug statute and repeal portions of the existing Kratom Consumer Protection Act.

What HB968 would do if enacted

Under HB968, possession, manufacture, sale, and distribution of mitragynine or 7-hydroxymitragynine would become criminal offenses rather than civil violations. Schedule I classification at the state level carries the same general framework as Alabama’s existing treatment of kratom: possession becomes a felony offense with potential prison time and substantial fines, and the product category becomes unavailable through legal retail channels. The specific penalty structure in HB968 would be set by the bill as enacted and is subject to legislative amendment during the process.

What HB968 status is today

As of April 2026, HB968 has not been enacted. Its legislative trajectory is uncertain. Some legislative analysts expect Georgia’s existing regulatory framework to prevail at least through the current session, with future-session revival a real possibility; others note that momentum in several neighboring states toward tighter restrictions on concentrated 7-OH could shift the political calculus. The honest answer to “will HB968 pass” is that nobody knows with confidence, and the bill status can change quickly during a legislative session.

What HB968 would signal about the region

If HB968 becomes law, Georgia would join Alabama, Arkansas, Indiana, Vermont, Wisconsin, Louisiana (banned August 2025), and Connecticut (banned March 25, 2026) as states that have fully banned kratom. Rhode Island was on the banned list until April 1, 2026, when a new regulatory framework took effect — the first U.S. state to reverse a kratom ban. Tennessee is on its own track: HB1649/SB1656, which would criminalize kratom statewide, passed both Tennessee chambers on April 16, 2026 and is currently awaiting Governor Bill Lee’s signature (effective July 1, 2026 if signed), as documented in our companion article on Tennessee kratom law. The regulatory direction across the Southeast is toward restriction, though the pace and severity varies by state.

Federal 7-OH scheduling is a separate track

State law is only part of the picture. At the federal level, kratom itself remains unscheduled under the Controlled Substances Act, but the status of concentrated 7-hydroxymitragynine products is actively in motion on a separate timeline.

On July 29, 2025, the FDA formally recommended to the DEA that concentrated 7-OH products be scheduled as Schedule I under the Controlled Substances Act. The FDA’s recommendation targeted 7-OH concentrates specifically, which the agency described as tablets, gummies, drink mixes, and shots containing elevated 7-OH concentrations. Natural whole-leaf kratom was not the focus of this recommendation. The DEA is reviewing the FDA recommendation through its standard rulemaking process, which involves a public-comment period before any final action. Timing is uncertain; federal scheduling decisions typically take months to years.

If concentrated 7-OH products are federally scheduled, they would become illegal to manufacture, sell, or possess nationwide, regardless of what any individual state does at its own level. Whole-leaf kratom would remain unscheduled at the federal level unless separately addressed. Our companion explainer on 7-OH versus whole-leaf kratom covers the pharmacology and regulatory distinction in more depth.

What this means for Georgia residents who are dependent on kratom or 7-OH

This is the part of the article that matters most if you are reading this page because you are struggling to stop using kratom or 7-OH, or because someone you care about is. The relevant fact: the legal status of kratom products does not affect whether treatment is available, effective, or covered by insurance.

Why buprenorphine works for kratom and 7-OH dependence

Kratom’s primary active alkaloids, mitragynine and 7-hydroxymitragynine, bind to the same mu-opioid receptors that fentanyl, heroin, and prescription opioids act on. Although kratom is not itself a classical opioid, the receptor activity means that the same medication-assisted treatment protocol used for opioid use disorder is clinically effective for kratom dependence. Buprenorphine, the active medication in Suboxone, Sublocade, and Brixadi, is a partial opioid agonist that relieves kratom withdrawal, suppresses craving, and provides a stable transition off kratom products over weeks rather than days.

The Georgia treatment infrastructure

Georgia Medicaid covers medication-assisted treatment for opioid use disorder through the Georgia Families managed care program, including the same buprenorphine-based medications used for kratom dependence. Georgia’s Medicaid care management organization (CMO) lineup is in transition in 2026, so members should call their specific plan or our intake team to confirm in-network status before scheduling. Commercial insurance coverage varies but is generally available through in-network outpatient clinics. Self-pay options are also available for patients without coverage.

Restoration Recovery’s Ringgold clinic is in Catoosa County, serving patients from across North Georgia including Catoosa, Walker, Whitfield, Murray, Dade, Gordon, and Chattooga counties. The three Tennessee-side clinics (Chattanooga, Cleveland, Soddy-Daisy) also see Georgia residents routinely, particularly from counties closest to the state line. For a broader map of where we serve, see our Find Treatment Near You directory.

What the first visit looks like

The intake process for kratom dependence is the same four-step flow used for all MAT candidates at Restoration Recovery: a DSM-5 assessment to confirm substance use disorder criteria, a COWS (Clinical Opiate Withdrawal Scale) score to identify where you are in withdrawal, a counseling session, and a visit with a prescribing physician who chooses and doses the appropriate medication. A first Suboxone induction typically happens at the first appointment; Sublocade or Brixadi injections require a stabilization period on daily Suboxone before the injection can be given. For a direct comparison of the buprenorphine formulations, see our Sublocade vs. Daily Suboxone decision-support page.

Common questions Georgia patients ask

Is kratom legal in Georgia in 2026?

As of April 2026, kratom is legal for adults aged 21 and older in Georgia under the 2019 Kratom Consumer Protection Act, with additional restrictions added by HB181 that took effect January 1, 2025. Products must be kept behind retail counters, labeled with mitragynine and 7-hydroxymitragynine content, and tested by a third-party lab. Legal status could change if HB968, which would classify mitragynine and 7-OH as Schedule I controlled substances, becomes law.

What does HB181 require for Georgia kratom retailers?

HB181, effective January 1, 2025, raises the minimum purchase age to 21, requires retailers to keep kratom products behind display counters or in secured displays accessible only through employee assistance, and mandates that products display mitragynine and 7-hydroxymitragynine content, recommended serving sizes, batch numbers, expiration dates, and 21-plus warnings. The law also caps 7-hydroxymitragynine at 2 percent of total alkaloid content and prohibits synthetic additives. Penalties for selling to minors begin at $1,000; labeling violations can reach $2,500.

Would HB968 make kratom illegal in Georgia?

HB968 is a proposal to classify mitragynine and 7-hydroxymitragynine as Schedule I controlled substances under Georgia law, which would make possession, sale, and distribution criminal offenses. If passed, HB968 would repeal portions of Georgia’s existing Kratom Consumer Protection Act framework and place kratom in the same legal category it currently occupies in Alabama and six other states. As of April 2026, HB968 has not been enacted; its trajectory remains uncertain.

Does legal status affect treatment for kratom dependence?

No. Treatment for kratom or 7-hydroxymitragynine dependence does not change based on the legal status of kratom products. Buprenorphine-based medication-assisted treatment (Suboxone, Sublocade, Brixadi) has an FDA-approved indication for opioid use disorder, and because kratom’s primary active compounds act on the same mu-opioid receptors, buprenorphine is clinically effective for kratom dependence as well. Insurance coverage, confidentiality protections under 42 CFR Part 2, and clinic-level care remain the same regardless of what state law does next.

Where can Georgia residents get treatment for kratom or 7-OH dependence?

Restoration Recovery operates an outpatient clinic in Ringgold, Georgia (Catoosa County) and three additional locations in Southeast Tennessee (Chattanooga, Cleveland, Soddy-Daisy). The Ringgold clinic accepts Georgia Medicaid through the Georgia Families managed care program, Medicare, Tricare, and most commercial plans. Georgia’s Medicaid CMO lineup is in transition in 2026, so members should call their specific plan or our intake team to confirm in-network status before scheduling. Same-week intake appointments are typically available for new patients. Medication-assisted treatment for kratom dependence follows the same buprenorphine-based protocol used for opioid use disorder.

Where to check current status

Legislation can shift during a legislative session. For the most current status of Georgia bills, the Georgia General Assembly maintains bill-tracking pages for each active bill at legis.ga.gov. Independent trackers like BillTrack50 and LegiScan also show committee actions, voting records, and full bill text. For the federal 7-OH picture, FDA and DEA press releases and notices in the Federal Register are the authoritative sources. We update our Tennessee kratom law article and this Georgia companion as bill status changes meaningfully.

This article is published for patient information only. It is not legal advice. If you have a specific legal question about your situation, consult a Georgia attorney licensed to practice in your jurisdiction.

If you are ready to stop

Whatever the Georgia General Assembly does with HB968 this year, the clinical reality for kratom and 7-OH dependence is stable. Buprenorphine-based MAT works, same-week appointments are available at our Ringgold clinic and our three Southeast Tennessee locations, and most insurance plans (including Georgia Medicaid through the Georgia Families program) cover treatment. Call 423-498-2000 or book a callback when you are ready.

Related reading